3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Pancreatic Neoplasms
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Resectable Pancreatic Cancer
1
Resectable Esophageal Cancer
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Locally Advanced Pancreatic Adenocarcinoma
1
Endometrial Neoplasms
1
Carcinosarcoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Interventions
pembrolizumab
35
Nivolumab
13
Cyclophosphamide
11
fludarabine
9
aldesleukin
9
atezolizumab
7
Magnetic Resonance Spectroscopy
7
Carboplatin
7
Specimen Handling
6
Ipilimumab
6
Early Intervention, Educational
6
Cisplatin
6
Trastuzumab
5
Paclitaxel
5
Methods
5
Biopsy
5
Bevacizumab
5
durvalumab
4
Vaccines
4
Surveys and Questionnaires
4
Radiotherapy
4
Papillomavirus Vaccines
4
Interleukin-2
4
Docetaxel
4
tisotumab vedotin
3
spartalizumab
3
fludarabine phosphate
3
cemiplimab
3
aflibercept
3
Tomography, X-Ray Computed
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Cervical Neoplasms
×
Colony-Stimulating Factors
×
Gastrointestinal
×
Clear all
NCT05269381
2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2
Recruiting
132 enrolled